Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3H1
- Development stage
- Phase 2
- Lead developer
- Titan Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intramuscular, Subcutaneous
01
Overview
3H1 (CeaVac) is a murine IgG1 monoclonal anti-idiotype antibody (Ab2) that serves as a molecular mimic of a specific epitope on the carcinoembryonic antigen (CEA). Developed as a cancer vaccine, 3H1 is designed to break immune tolerance to CEA, a self-antigen that is overexpressed in various adenocarcinomas, including colorectal and non-small cell lung cancers. By acting as an internal image of CEA, the antibody induces an anti-anti-idiotypic (Ab3) immune response that cross-reacts with the actual CEA on tumor cells, thereby stimulating both humoral and cellular (T-cell) immunity. The drug was primarily developed by researchers at the University of Kentucky and licensed to Titan Pharmaceuticals, but development was largely discontinued after failing to meet primary endpoints in Phase III clinical trials for colorectal cancer.
- Brand names
- CeaVac
- Other names
- 3H1 anti-idiotype antibodyanti-idiotype 3H1anti-idiotype3H1anti-idiotype-3H1CeaVac vaccine
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on 3H1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3H1.